mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities
Abstract
mRNA-based cancer vaccines have emerged as a promising platform for therapeutic cancer immunotherapy because of their ability to encode tumor-associated antigens, tumor-specific antigens, and patient-specific neoantigens and to induce antigen-specific immune responses. Their flexible and cell-free manufacturing enables rapid adaptation and facilitates the development of personalized vaccines based on individual tumor mutations and HLA profiles. However, the clinical translation of mRNA-based cancer vaccines remains challenging because of difficulties in neoantigen identification, maintaining mRNA stability, achieving efficient intracellular and tissue-specific delivery and endosomal escape, optimizing antigen expression, and overcoming tumor heterogeneity, and immunosuppressive tumor microenvironments. Advances in mRNA engineering, including sequence optimization, modified nucleosides, cap and UTR optimization, and lipid nanoparticle-based delivery, have improved RNA stability, cellular uptake, antigen expression, and immune activation in various experimental and clinical settings. This review discusses the principles of mRNA-based cancer vaccines, strategies for neoantigen identification and vaccine development, mRNA production and formulation, nanoparticle-mediated delivery, major challenges affecting stability, targeting, expression, and immune stimulation, and emerging clinical applications. Particular emphasis is placed on personalized neoantigen vaccines and combination approaches with immune checkpoint inhibitors. Continued integration of RNA engineering, nanotechnology, computational antigen prediction, and precision immunotherapy may enable more effective and clinically adaptable mRNA-based cancer vaccines.
Related
- Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges
- The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges
- Neuroimmune crosstalk in cancer: emerging immunotherapeutic opportunities.
- Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
- Challenges and opportunities in emotion dynamics research: an interdisciplinary perspective
BibTeX
@article{kulshreshtha2026mrnabased,
title = {{mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities}},
author = {Shweta Kulshreshtha and Umesh Kumar and V. V. Sathibabu Uddandrao and Shoorvir Singh and Akshata Mandloi and Himanshu Gogoi},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1984876},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1984876},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities
AU - Shweta Kulshreshtha
AU - Umesh Kumar
AU - V. V. Sathibabu Uddandrao
AU - Shoorvir Singh
AU - Akshata Mandloi
AU - Himanshu Gogoi
PY - 2026
DA - 2026/11/10
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1984876
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1984876
AB - mRNA-based cancer vaccines have emerged as a promising platform for therapeutic cancer immunotherapy because of their ability to encode tumor-associated antigens, tumor-specific antigens, and patient-specific neoantigens and to induce antigen-specific immune responses. Their flexible and cell-free manufacturing enables rapid adaptation and facilitates the development of personalized vaccines based on individual tumor mutations and HLA profiles. However, the clinical translation of mRNA-based cancer vaccines remains challenging because of difficulties in neoantigen identification, maintaining mRNA stability, achieving efficient intracellular and tissue-specific delivery and endosomal escape, optimizing antigen expression, and overcoming tumor heterogeneity, and immunosuppressive tumor microenvironments. Advances in mRNA engineering, including sequence optimization, modified nucleosides, cap and UTR optimization, and lipid nanoparticle-based delivery, have improved RNA stability, cellular uptake, antigen expression, and immune activation in various experimental and clinical settings. This review discusses the principles of mRNA-based cancer vaccines, strategies for neoantigen identification and vaccine development, mRNA production and formulation, nanoparticle-mediated delivery, major challenges affecting stability, targeting, expression, and immune stimulation, and emerging clinical applications. Particular emphasis is placed on personalized neoantigen vaccines and combination approaches with immune checkpoint inhibitors. Continued integration of RNA engineering, nanotechnology, computational antigen prediction, and precision immunotherapy may enable more effective and clinically adaptable mRNA-based cancer vaccines.
SN - 1663-9812
ER -